Pal, I., Grilo, A. M. S., Gaspary, A., Das Sharma, S., Scotto, L., O’Connor, O. A., Jovanovic, M., Deng, C., & Berchowitz, L. E. (2022). Inhibition of casein kinase 1δ disrupts translation initiation and exerts potent antilymphoma activity. Blood Advances, 6(14), 4157–4161. https://doi.org/10.1182/bloodadvances.2021006833

Keren, D. F., Bocsi, G., Billman, B. L., Etzell, J., Faix, J. D., Kumar, S., Lipe, B., McCudden, C., Montgomery, R., Murray, D. L., Rai, A. J., Redondo, T. C., Souter, L., Ventura, C. B., & Ansari, M. Q. (2021). Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies. Archives of Pathology & Laboratory Medicine, 146(5), 575–590. https://doi.org/10.5858/arpa.2020-0794-cp

Diamond, J. R., Boni, V., Lim, E., Nowakowski, G., Cordoba, R., Morillo, D., Valencia, R., Genvresse, I., Merz, C., Boix, O., Frigault, M. M., Greer, J. M., Hamdy, A. M., Huang, X., Izumi, R., Wong, H., & Moreno, V. (2022). First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. Clinical Cancer Research, 28(7), 1285–1293. https://doi.org/10.1158/1078-0432.ccr-21-3617

Gregory, G. P., Kumar, S., Wang, D., Mahadevan, D., Walker, P., Wagner-Johnston, N., Escobar, C., Bannerji, R., Bhutani, D., Chang, J., Hernandez-Ilizaliturri, F. J., Klein, A., Pagel, J. M., Rybka, W., Yee, A. J., Mohrbacher, A., Huang, M., Farooqui, M., Marinello, P., & Quach, H. (2022). Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. Blood Advances, 6(4), 1232–1242. https://doi.org/10.1182/bloodadvances.2021005872

Mato, A. R., Davids, M. S., Sharman, J., Roeker, L. E., Kay, N., Kater, A. P., Rogers, K., Thompson, M. C., Rhodes, J., Goy, A., Skarbnik, A., Schuster, S. J., Tam, C. S., Eyre, T. A., O’Brien, S., Nabhan, C., Lamanna, N., Sun, C., Shadman, M., … Woyach, J. A. (2021). Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What’s Past Is Prologue” (Shakespeare). Clinical Cancer Research, 28(4), 603–608. https://doi.org/10.1158/1078-0432.ccr-21-1237

Gibson, S. E., Liu, Y.-C., Yatsenko, S. A., Barasch, N. J., & Swerdlow, S. H. (2022). Histopathologic, immunophenotypic, and mutational landscape of follicular lymphomas with plasmacytic differentiation. Modern Pathology, 35(1), 60–68. https://doi.org/10.1038/s41379-021-00938-z

van Vollenhoven, R. F., Bertsias, G., Doria, A., Isenberg, D., Morand, E., Petri, M. A., Pons-Estel, B. A., Rahman, A., Ugarte-Gil, M. F., Voskuyl, A., Arnaud, L., Bruce, I. N., Cervera, R., Costedoat-Chalumeau, N., Gordon, C., Houssiau, F. A., Mosca, M., Schneider, M., Ward, M. M., … Aranow, C. (2021). 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science & Medicine, 8(1), e000538. https://doi.org/10.1136/lupus-2021-000538

Lipsky, A. H., Hill, B. T., Winter, A. M., Jurcic, J. G., Heaney, M. L., Rosenblat, T. L., Chiaramonte, M., Weissbrot, H., & Lamanna, N. (2021). High Rates of Undetectable Minimal Residual Disease Remissions with Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL). Blood, 138(Supplement 1), 1555–1555. https://doi.org/10.1182/blood-2021-150914

Pemmaraju, N., Kantarjian, H., Sweet, K., Wang, E. S., Lane, A. A., Ali, H., Stein, A. S., Yacoub, A., Rizzieri, D. A., Vasu, S., Gupta, V., Lee, S., Schiller, G. J., Foran, J. M., Taparia, M. S., Rosenblat, T. L., Walter, R. B., Sieminski, D., Anant, M., … Konopleva, M. (2021). Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies. Blood, 138(Supplement 1), 2318–2318. https://doi.org/10.1182/blood-2021-145344

Ricker, E. C., Ryu, Y. K., & Amengual, J. E. (2021). Daratumumab Plus Chemotherapy Induces Complete Responses in a Consecutive Series of Four Patients with Plasmablastic Lymphoma. Blood, 138(Supplement 1), 4573–4573. https://doi.org/10.1182/blood-2021-150800

Koffman, Dr. B., Stewart, C., Avruch, L., Bailey, N., Brumble, R., Byrd, J. C., Danilov, A. V., Davids, M. S., Furman, R., Jain, N., Kay, N. E., Lamanna, N., Mato, A. R., Skarbnik, A., Ujjani, C. S., & Pagel, J. M. (2021). Awareness, Knowledge, and Preferences of United States (US) Patients with Chronic Lymphocytic Leukemia (CLL) and Their Caregivers Related to Finite Duration (FD) Therapy and Minimal (Measurable) Residual Disease (MRD). Blood, 138(Supplement 1), 1927–1927. https://doi.org/10.1182/blood-2021-145046

Thompson, M. C., Roeker, L. E., Coombs, C. C., Jensen, J. L., Kamdar, M., Skarbnik, A., Pagel, J. M., Bailey, N., Pu, J. J., Jacobs, R., Hill, B. T., Brander, D. M., Shadman, M., Ujjani, C. S., Battiato, K. E., Komari, C. J., Sacchi De Camargo Correia, G., Aronson, J. H., Rhodes, J. M., … Mato, A. R. (2021). Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton’s Tyrosine Kinase Inhibitor and Venetoclax. Blood, 138(Supplement 1), 2628–2628. https://doi.org/10.1182/blood-2021-150751

Love, C., Pillai, R., Ondrejka, S. L., Bhagat, G., Chadburn, A., McKinney, M., Koff, J. L., Soliman, D. S., Czader, M., Louissaint, A., Li, S., Ong, C. K., Behdad, A., Evens, A. M., Natkunam, Y., Norgaard, P. H., Leppa, S., Tse, E., Chapman, J. R., … Dave, S. (2021). The Atlas of Blood Cancer Genomes (ABCG) Project: A Comprehensive Molecular Characterization of Leukemias and Lymphomas. Blood, 138(Supplement 1), 2213–2213. https://doi.org/10.1182/blood-2021-151346

Wang, M., Shah, N. N., Alencar, A. J., Gerson, J. N., Patel, M. R., Fakhri, B., Jurczak, W., Tan, X. N., Lewis, K., Fenske, T. S., Coombs, C. C., Flinn, I. W., Lewis, D. J., Le Gouill, S., Palomba, M. L., Woyach, J. A., Pagel, J. M., Lamanna, N., Cohen, J. B., … Cheah, C. Y. (2021). Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study. Blood, 138(Supplement 1), 381–381. https://doi.org/10.1182/blood-2021-149138

Hijiya, N., Kapoor, S., Descamps, L., Bayar, M. A., & Ramscar, N. (2021). Trial in Progress: A Multicenter, Open-Label, Phase Ib/II Study to Determine the Dose and Safety of Asciminib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated with ≥1 Prior Tyrosine Kinase Inhibitor. Blood, 138(Supplement 1), 2561–2561. https://doi.org/10.1182/blood-2021-151198

Prockop, S., Mahadeo, K. M., Beitinjaneh, A., Choquet, S., Stiff, P., Reshef, R., Satyanarayana, G., Dahiya, S., Parmar, H., Ye, W., Gamelin, L., & Dinavahi, R. (2021). Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). Blood, 138(Supplement 1), 301–301. https://doi.org/10.1182/blood-2021-147274

Youn, M., Smith, S. M., Lee, A. G., Chae, H.-D., Spiteri, E., Erdmann, J., Galperin, I., Murphy, L. C., Donato, M., Abidi, P., Bittencourt, H., Lacayo, N. J., Dahl, G., Aftandilian, C., Davis, K. L., Matthews, J. A., Kornblau, S. M., Huang, M., Sumarsono, N., … Sakamoto, K. M. (2021). Gene Expression Analysis of CML Patients across the Age Spectrum. Blood, 138(Supplement 1), 1473–1473. https://doi.org/10.1182/blood-2021-148701

Pennesi, E., Brivio, E., Willemse, M. E., Huitema, A. D. R., Chandra, S., Vijayakumar, A., Van Der Velden, V. H. J., Beverloo, H. B., Durairaj, C., Viqueira, A., Ingrosso, A., Locatelli, F., Motwani, J., Bourquin, J.-P., Bautista Sirvent, F. J., Rizzari, C., Petit, A., Lancaster, D., Metzler, M., … Zwaan, C. M. (2021). A Phase I/II Study of Bosutinib in Pediatric Patients with Resistant/Intolerant or Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Study ITCC (Innovative Therapies for Children with Cancer European Consortium) 054 and COG (Children’s Oncology Group Consortium) AAML1921: Results from the Phase I Trial in Resistant/Intolerant Patients. Blood, 138(Supplement 1), 2558–2558. https://doi.org/10.1182/blood-2021-145709

Mato, A. R., Pagel, J. M., Coombs, C. C., Shah, N. N., Lamanna, N., Munir, T., Lech-Marańda, E., Eyre, T. A., Woyach, J. A., Wierda, W. G., Cheah, C. Y., Cohen, J. B., Roeker, L. E., Patel, M. R., Fakhri, B., Barve, M. A., Tam, C. S., Lewis, D. J., Gerson, J. N., … Jurczak, W. (2021). Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study. Blood, 138(Supplement 1), 391–391. https://doi.org/10.1182/blood-2021-147599

Lee, H. J., Choi, M., Siddiqi, T., Barrientos, J., Wierda, W. G., Isufi, I., Tuscano, J., Lamanna, N., Subbiah, S., Koff, J. L., Leslie, L. A., Goldenberg, A., Chung, G. G., Breitmeyer, J. B., Yazji, S., Wang, Y., Wang, M., Jamieson, C., & Kipps, T. J. (2021). Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL). Blood, 138(Supplement 1), 3534–3534. https://doi.org/10.1182/blood-2021-148779

Herrera, A. F., Ahn, K. W., Litovich, C., Chen, Y., Assal, A., Bashir, Q., Bayer, R.-L., Coleman, M., DeFilipp, Z., Farhadfar, N., Greenwood, M., Hahn, T., Horwitz, M., Jacobson, C., Jaglowski, S., Lachance, S., Langston, A., Mattar, B., Maziarz, R. T., … Hamadani, M. (2021). Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma–type Richter syndrome. Blood Advances, 5(18), 3528–3539. https://doi.org/10.1182/bloodadvances.2021004865